Angiogenesis inhibition:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
2010
|
| Schriftenreihe: | Recent results in cancer research
180 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV, 231 S. Ill., graph. Darst. |
| ISBN: | 9783540782803 9783540782810 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023078912 | ||
| 003 | DE-604 | ||
| 005 | 20091217 | ||
| 007 | t | ||
| 008 | 080114s2010 gw ad|| |||| 00||| eng d | ||
| 020 | |a 9783540782803 |9 978-3-540-78280-3 | ||
| 020 | |a 9783540782810 |9 978-3-540-78281-0 | ||
| 035 | |a (OCoLC)498875297 | ||
| 035 | |a (DE-599)BVBBV023078912 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BE | ||
| 049 | |a DE-29 |a DE-19 |a DE-12 | ||
| 050 | 0 | |a RC261 | |
| 084 | |a XH 1800 |0 (DE-625)152873:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Angiogenesis inhibition |c Rüdiger Liersch ... (eds.) |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 2010 | |
| 300 | |a XIV, 231 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Recent results in cancer research |v 180 | |
| 650 | 4 | |a Angiogenesis Inhibitors | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 4 | |a Neovascularization inhibitors | |
| 650 | 4 | |a Neovascularization, Pathologic |x drug therapy | |
| 650 | 0 | 7 | |a Angiogenese |0 (DE-588)4142449-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Inhibition |0 (DE-588)4273127-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Tumorwachstum |0 (DE-588)4186432-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Tumorwachstum |0 (DE-588)4186432-3 |D s |
| 689 | 0 | 1 | |a Angiogenese |0 (DE-588)4142449-9 |D s |
| 689 | 0 | 2 | |a Inhibition |0 (DE-588)4273127-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Liersch, Rüdiger |e Sonstige |4 oth | |
| 830 | 0 | |a Recent results in cancer research |v 180 |w (DE-604)BV000000043 |9 180 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016281962&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016281962 | ||
Datensatz im Suchindex
| _version_ | 1804137325558497280 |
|---|---|
| adam_text | Titel: Angiogenesis inhibition
Autor: Liersch, Rüdiger
Jahr: 2010
1 Introduction I
Judah Folkman 1
2 Angiopoietins 3
Yvonne Rciss
2.1 Introduction 3
2.2 Importance of the Angiopoietin/Tie System During
Developmental Angiogenesis 4
2.3 Angiopoietins and Tumor-Associated Angiogenesis 6
2.4 Therapeutic Implications 9
2.5 Conclusions 9
References 10
3 HIF-la and Cancer Therapy 15
Mei Yee Koh, Taly R. Spivak-Kroizman, and Garth Powis
3.1 Background 15
3.2 Molecular and Cellular Biology of HIF-1 16
3.3 HIF-1 Regulation 16
3.3.1 Regulation of HIF-la Translation 16
3.3.2 Regulation of HIF-la Degradation 20
3.3.3 Regulation of HIF-1 Transactivation 21
3.4 Relationship Between HIF-1 and Other Key Oncogenic Pathways... 22
3.4.1 HIF-1 Activation by Growth Factors 22
3.4.2 Interplay Between HIF-1 and the p53 Tumor Suppressor 22
3.4.3 Interplay Between HIF-1 and Myc 22
3.5 Hypoxia and HIF-1 Effects on Cancer Stem Cells 23
3.6 HIF-I as a Cancer Drug Target 23
3.7 HIF-1 Inhibitors 24
3.8 Conclusions 27
References 28
vi Contents
4 Chemokines 35
Andreas Hippe, Bernhard Homey, and Anja Mueller-Homey
4.1 Angiogenesis 35
4.2 Chemokines in Angiogenesis 37
4.2.1 CXC Chemokine Subfamily 37
4.2.2 CC Chemokine Subfamily 38
4.2.3 CX3C Chemokine Subfamily 39
4.3 Chemokine Receptor Repertoire of Endothelial Cells 39
4.4 Angiogenesis, Chemokines, and Cancer 40
4.4.1 Breast Cancer 41
4.4.2 Malignant Melanoma 41
4.4.3 Lung Cancer 42
4.5 Inhibition of Chemokine-Induced Angiogenesis
as a Therapeutic Strategy 43
References 45
5 Angiogenesis Inhibition in Cancer Therapy 51
Iris Appelmann, Rudiger Liersch, Torsten Kessler, Rolf M. Mesters,
and Wolfgang E. Berdel
5.1 Introduction 51
5.2 VEGF 52
5.2.1 VEGF Isoforms and Their Expression 52
5.2.2 VEGF Receptors 53
5.2.3 Structure of VEGFR1 and VEGFR2 54
5.2.4 Signaling and Biological Functions of VEGFR1 55
5.2.5 Expression and Signaling of VEGFR2 56
5.2.6 VEGF and Malignancy 57
5.3 PDGF 59
5.3.1 Platelet-Derived Growth Factor and Its Isoforms 59
5.3.2 PDGF Receptors 61
5.3.3 PDGF Ligand and Receptor Expression Patterns 61
5.3.4 PDGF Biosynthesis, Secretion, and Distribution 62
5.3.5 PDGFR Signal Transduction 64
5.3.6 Cellular Responses to PDGFR Signaling 65
5.3.7 PDGF and PDGFR in Malignancy 67
References 69
6 Vascular Integrins: Therapeutic and Imaging Targets
of Tumor Angiogenesis 83
Curzio Riiegg and Gian Carlo Alghisi
6.1 Integrin Structure 83
6.2 Integrin Functions 84
6.2.1 Cell Adhesion 84
6.2.2 Cell Signaling 84
Contents vjj
6.3 Integrins in Tumor Angiogenesis 86
6.4 Integrin Antagonists with Antiangiogenic Activities 87
6.4.1 Antibodies 87
6.4.2 Endogenous Antagonists 89
6.4.3 Peptides 90
6.4.4 Non-peptidic Inhibitors 90
6.5 Open Questions and Current Developments 91
6.5.1 Most Relevant Targets 91
6.5.2 Combination Therapies 91
6.5.3 Drug Targeting 92
6.5.4 Tumor Imaging 93
6.6 Future Directions 93
6.6.1 New Generation of Extracellular Antagonists 93
6.6.2 Targeting the Integrin Intracellular Domains 94
6.6.3 Targeting Angiogenic Precursor Cells
and Inflammatory Cells 94
6.7 Conclusions 94
References 95
7 PDGF and Vessel Maturation 103
Carina Hellberg, Arne Ostman, and C.-H. Heldin
7.1 Introduction 103
7.2 The PDGF Family 103
7.3 Pericytes 104
7.3.1 Role of Pericytes 104
7.3.2 Identification of Pericytes 104
7.3.3 The Origin of Pericytes 105
7.4 Vessel Maturation 106
7.4.1 Normal Vessels 106
7.4.2 Tumor Vessels 108
7.5 Tumor Therapy Targeting PDGF Receptors on the Vasculature .. 109
7.5.1 Antiangiogenic Therapy Targeting Pericytes 110
7.5.2 Improving the Efficacy of Conventional Therapies 110
7.6 Future Perspectives Ill
References 112
8 Lymphangiogenesis in Cancer: Current Perspectives 115
Rudiger Liersch, Christoph Biermann, Rolf M. Mesters,
and Wolfgang E. Berdel
8.1 Introduction 5
8.2 Embryonic Lymphatic Development 116
8.3 The Lymphatic Function 17
8.3.1 Molecular Players in the Regulation
of Lymphangiogenesis 8
viii Contents
8.4 Pathology of the Lymphatic Vasculature 122
8.4.1 Secondary Lymphedema 122
8.4.2 Primary Lymphedema 123
8.5 Role of Lymphangiogenesis in Cancer 124
8.5.1 Lymphvascular Invasion 124
8.5.2 Tumor-Lymphangiogenesis 124
8.5.3 Lymphatic Endothelial Cell Activation 125
8.5.4 Lymph Node Lymphangiogenesis 125
8.6 Targeting Lymphangiogenesis 126
8.6.1 Antibodies 127
8.6.2 Soluble Receptors 127
8.6.3 Small Molecule Inhibitor 127
8.7 Conclusions 127
References 127
9 Compounds in Clinical Phase HI and beyond 137
Torsten Kessler, Michael Bayer, Christian Schwoppe, Riidiger Liersch,
Rolf M. Mesters, and Wolfgang E. Berdel
9.1 Introduction 137
9.1.1 Anti-VEGF Antibody (Bevacizumab, Avastin) 138
9.1.2 Aflibercept (VEGF - Trap) 140
9.1.2.1 Sorafenib (Nexavar) 140
9.1.3 Sunitinib Malate (SU11248; Sutent) 144
9.1.4 Axitinib (AG-013736) 146
9.1.5 Cediranib (AZD2171; Recentin) 147
9.1.6 Vandetanib (ZD6474; Zactima) 148
9.1.7 Vatalanib (PTK787/ZK222584) 149
9.1.8 Endostatin (rh-Endostatin, YH-16, Endostar) 150
9.1.9 Thalidomide 151
9.1.10 Vascular Disrupting Agents 152
9.1.11 Accidental Antiangiogenesis Agents 154
9.1.12 Conclusions and Future Perspectives 155
References 156
10 Metronomic Chemotherapy: Principles and Lessons Learned
from Applications in the Treatment of Metastatic Prostate Cancer 165
Urban Emtnenegger, Giulio Francia, Yuval Shaked,
and Robert S. Kerbel
10.1 Introduction 165
10.2 Mechanisms of Action of Metronomic Chemotherapy 166
10.2.1 Preferential Antiproliferative Effects of Metronomic
Chemotherapy Toward Endothelial Cells 167
10.2.2 Circulating Bone Marrow-Derived Endothelial
Precursor Cells as Targets of Metronomic Chemotherapy 167
Contents j
10.2.2.1 Benefit of Combined Bolus and Metronomic
Chemotherapy Administration 8
10.2.2.2 CEPs and Optimal Biological Dose of Antiangiogenic Agents... 169
10.2.3 Mechanisms of Action Summarized 170
10.3 Metronomic Chemotherapy for the Treatment of Metastatic
Castration-Resistant Prostate Cancer 70
10.3.1 From Bench to Bedside l72
10.3.2 Key Findings of Metronomic Trials in Castration-Resistant
Prostate Cancer and Emerging Questions 74
10.3.2.1 Choice of Cytotoxic Drugs Used in Metronomic Regimens 176
10.3.2.2 Optimal Biological Dose 1?6
10.3.2.3 Combination Therapies 77
10.3.3 Integration of Metronomic Chemotherapy into
Current Standards of Practice for Prostate Cancer 78
10.4 Conclusions and Perspectives 7**
References
11 Targeting Inflammatory Cells to Improve Anti-VEGF
Therapies in Oncology -1
Hans-Peter Gerber, Ezogelin Olazoglu, and Iqbal S. Grewal
11.1 Role of Bone Marrow-Derived Tumor Infiltrating
Cells in Tumor Angiogenesis
11.2 Endothelial Progenitor Cells (EPCs) and Circulatory Endothelial
Progenitor Cells (CEPs) 186
11.3 Tumor-Associated Macrophages °9
11.4 CDllb+Grl+Myeloid-Derived Suppressor Cells 91
11.5 Lymphocytes and Mast Cells (MCs) 191
11.6 Neutrophils 192
11.7 Therapeutic Targets to Overcome Anti-VEGF Refractoriness.... 193
11.7.1 Bv8 193
11.8 VEGF-B,-C,-D, and P1GF l93
11.9 Targeting MDSCs and TAMs ™
11.10 Targeting EPCs 195
11.11 Conclusions
References
12 Antibody-Based Vascular Tumor Targeting
Christoph Schliemann and Dario Neri
12.1 Concept and Definitions
12.2 Discovery of Novel Vascular Targets -
12.3 Validated Markers of the Tumor Vasculature. • •
12.3.1 Extra Domains of Fibronectin ¦
12.3.2 Large Isoforms of Tenascin C ¦ • 205
12.3.3 Phosphatidylserine -
x Contents
12.3.4 Annexin Al 206
12.3.5 Prostate-Specific Membrane Antigen (PSMA) 207
12.3.6 Endoglin 207
12.3.7 Integrins 207
12.3.8 Vascular Endothelial Growth Factors (VEGFs) and Receptors ... 208
12.3.9 Nucleolin 208
12.4 Vascular Tumor Targeting: Imaging Applications 208
12.5 Vascular Tumor Targeting: Therapeutic Applications 209
References 212
13 Caveolae and Cancer 217
Kerri A. Massey and Jan E. Schnitzer
13.1 Vascular Endothelium 217
13.2 Caveolae Structure 218
13.3 Isolation of Caveolae 218
13.4 Caveolae in Signal Transduction 219
13.5 Caveolae as Active Transport Vesicles 220
13.6 Vascular Targeting 221
13.7 Phage Display Libraries 222
13.8 Large-Scale Approaches 223
13.9 Reducing Complexity 223
13.10 Tissue-Specific Targets 224
13.11 Tumor-Specific Targets 225
13.12 Clinical Implications 226
References 227
|
| adam_txt |
Titel: Angiogenesis inhibition
Autor: Liersch, Rüdiger
Jahr: 2010
1 Introduction I
Judah Folkman 1
2 Angiopoietins 3
Yvonne Rciss
2.1 Introduction 3
2.2 Importance of the Angiopoietin/Tie System During
Developmental Angiogenesis 4
2.3 Angiopoietins and Tumor-Associated Angiogenesis 6
2.4 Therapeutic Implications 9
2.5 Conclusions 9
References 10
3 HIF-la and Cancer Therapy 15
Mei Yee Koh, Taly R. Spivak-Kroizman, and Garth Powis
3.1 Background 15
3.2 Molecular and Cellular Biology of HIF-1 16
3.3 HIF-1 Regulation 16
3.3.1 Regulation of HIF-la Translation 16
3.3.2 Regulation of HIF-la Degradation 20
3.3.3 Regulation of HIF-1 Transactivation 21
3.4 Relationship Between HIF-1 and Other Key Oncogenic Pathways. 22
3.4.1 HIF-1 Activation by Growth Factors 22
3.4.2 Interplay Between HIF-1 and the p53 Tumor Suppressor 22
3.4.3 Interplay Between HIF-1 and Myc 22
3.5 Hypoxia and HIF-1 Effects on Cancer Stem Cells 23
3.6 HIF-I as a Cancer Drug Target 23
3.7 HIF-1 Inhibitors 24
3.8 Conclusions 27
References 28
vi Contents
4 Chemokines 35
Andreas Hippe, Bernhard Homey, and Anja Mueller-Homey
4.1 Angiogenesis 35
4.2 Chemokines in Angiogenesis 37
4.2.1 CXC Chemokine Subfamily 37
4.2.2 CC Chemokine Subfamily 38
4.2.3 CX3C Chemokine Subfamily 39
4.3 Chemokine Receptor Repertoire of Endothelial Cells 39
4.4 Angiogenesis, Chemokines, and Cancer 40
4.4.1 Breast Cancer 41
4.4.2 Malignant Melanoma 41
4.4.3 Lung Cancer 42
4.5 Inhibition of Chemokine-Induced Angiogenesis
as a Therapeutic Strategy 43
References 45
5 Angiogenesis Inhibition in Cancer Therapy 51
Iris Appelmann, Rudiger Liersch, Torsten Kessler, Rolf M. Mesters,
and Wolfgang E. Berdel
5.1 Introduction 51
5.2 VEGF 52
5.2.1 VEGF Isoforms and Their Expression 52
5.2.2 VEGF Receptors 53
5.2.3 Structure of VEGFR1 and VEGFR2 54
5.2.4 Signaling and Biological Functions of VEGFR1 55
5.2.5 Expression and Signaling of VEGFR2 56
5.2.6 VEGF and Malignancy 57
5.3 PDGF 59
5.3.1 Platelet-Derived Growth Factor and Its Isoforms 59
5.3.2 PDGF Receptors 61
5.3.3 PDGF Ligand and Receptor Expression Patterns 61
5.3.4 PDGF Biosynthesis, Secretion, and Distribution 62
5.3.5 PDGFR Signal Transduction 64
5.3.6 Cellular Responses to PDGFR Signaling 65
5.3.7 PDGF and PDGFR in Malignancy 67
References 69
6 Vascular Integrins: Therapeutic and Imaging Targets
of Tumor Angiogenesis 83
Curzio Riiegg and Gian Carlo Alghisi
6.1 Integrin Structure 83
6.2 Integrin Functions 84
6.2.1 Cell Adhesion 84
6.2.2 Cell Signaling 84
Contents vjj
6.3 Integrins in Tumor Angiogenesis 86
6.4 Integrin Antagonists with Antiangiogenic Activities 87
6.4.1 Antibodies 87
6.4.2 Endogenous Antagonists 89
6.4.3 Peptides 90
6.4.4 Non-peptidic Inhibitors 90
6.5 Open Questions and Current Developments 91
6.5.1 Most Relevant Targets 91
6.5.2 Combination Therapies 91
6.5.3 Drug Targeting 92
6.5.4 Tumor Imaging 93
6.6 Future Directions 93
6.6.1 New Generation of Extracellular Antagonists 93
6.6.2 Targeting the Integrin Intracellular Domains 94
6.6.3 Targeting Angiogenic Precursor Cells
and Inflammatory Cells 94
6.7 Conclusions 94
References 95
7 PDGF and Vessel Maturation 103
Carina Hellberg, Arne Ostman, and C.-H. Heldin
7.1 Introduction 103
7.2 The PDGF Family 103
7.3 Pericytes 104
7.3.1 Role of Pericytes 104
7.3.2 Identification of Pericytes 104
7.3.3 The Origin of Pericytes 105
7.4 Vessel Maturation 106
7.4.1 Normal Vessels 106
7.4.2 Tumor Vessels 108
7.5 Tumor Therapy Targeting PDGF Receptors on the Vasculature . 109
7.5.1 Antiangiogenic Therapy Targeting Pericytes 110
7.5.2 Improving the Efficacy of Conventional Therapies 110
7.6 Future Perspectives Ill
References 112
8 Lymphangiogenesis in Cancer: Current Perspectives 115
Rudiger Liersch, Christoph Biermann, Rolf M. Mesters,
and Wolfgang E. Berdel
8.1 Introduction "5
8.2 Embryonic Lymphatic Development 116
8.3 The Lymphatic Function ' 17
8.3.1 Molecular Players in the Regulation
of Lymphangiogenesis "8
viii Contents
8.4 Pathology of the Lymphatic Vasculature 122
8.4.1 Secondary Lymphedema 122
8.4.2 Primary Lymphedema 123
8.5 Role of Lymphangiogenesis in Cancer 124
8.5.1 Lymphvascular Invasion 124
8.5.2 Tumor-Lymphangiogenesis 124
8.5.3 Lymphatic Endothelial Cell Activation 125
8.5.4 Lymph Node Lymphangiogenesis 125
8.6 Targeting Lymphangiogenesis 126
8.6.1 Antibodies 127
8.6.2 Soluble Receptors 127
8.6.3 Small Molecule Inhibitor 127
8.7 Conclusions 127
References 127
9 Compounds in Clinical Phase HI and beyond 137
Torsten Kessler, Michael Bayer, Christian Schwoppe, Riidiger Liersch,
Rolf M. Mesters, and Wolfgang E. Berdel
9.1 Introduction 137
9.1.1 Anti-VEGF Antibody (Bevacizumab, Avastin) 138
9.1.2 Aflibercept (VEGF - Trap) 140
9.1.2.1 Sorafenib (Nexavar) 140
9.1.3 Sunitinib Malate (SU11248; Sutent) 144
9.1.4 Axitinib (AG-013736) 146
9.1.5 Cediranib (AZD2171; Recentin) 147
9.1.6 Vandetanib (ZD6474; Zactima) 148
9.1.7 Vatalanib (PTK787/ZK222584) 149
9.1.8 Endostatin (rh-Endostatin, YH-16, Endostar) 150
9.1.9 Thalidomide 151
9.1.10 Vascular Disrupting Agents 152
9.1.11 Accidental Antiangiogenesis Agents 154
9.1.12 Conclusions and Future Perspectives 155
References 156
10 Metronomic Chemotherapy: Principles and Lessons Learned
from Applications in the Treatment of Metastatic Prostate Cancer 165
Urban Emtnenegger, Giulio Francia, Yuval Shaked,
and Robert S. Kerbel
10.1 Introduction 165
10.2 Mechanisms of Action of Metronomic Chemotherapy 166
10.2.1 Preferential Antiproliferative Effects of Metronomic
Chemotherapy Toward Endothelial Cells 167
10.2.2 Circulating Bone Marrow-Derived Endothelial
Precursor Cells as Targets of Metronomic Chemotherapy 167
Contents j
10.2.2.1 Benefit of Combined Bolus and Metronomic
Chemotherapy Administration " 8
10.2.2.2 CEPs and Optimal Biological Dose of Antiangiogenic Agents. 169
10.2.3 Mechanisms of Action Summarized 170
10.3 Metronomic Chemotherapy for the Treatment of Metastatic
Castration-Resistant Prostate Cancer '70
10.3.1 From Bench to Bedside l72
10.3.2 Key Findings of Metronomic Trials in Castration-Resistant
Prostate Cancer and Emerging Questions '74
10.3.2.1 Choice of Cytotoxic Drugs Used in Metronomic Regimens 176
10.3.2.2 Optimal Biological Dose 1?6
10.3.2.3 Combination Therapies '77
10.3.3 Integration of Metronomic Chemotherapy into
Current Standards of Practice for Prostate Cancer ' 78
10.4 Conclusions and Perspectives '7**
References
11 Targeting Inflammatory Cells to Improve Anti-VEGF
Therapies in Oncology ' "-1
Hans-Peter Gerber, Ezogelin Olazoglu, and Iqbal S. Grewal
11.1 Role of Bone Marrow-Derived Tumor Infiltrating
Cells in Tumor Angiogenesis
11.2 Endothelial Progenitor Cells (EPCs) and Circulatory Endothelial
Progenitor Cells (CEPs) 186
11.3 Tumor-Associated Macrophages °9
11.4 CDllb+Grl+Myeloid-Derived Suppressor Cells '91
11.5 Lymphocytes and Mast Cells (MCs) 191
11.6 Neutrophils 192
11.7 Therapeutic Targets to Overcome Anti-VEGF Refractoriness. 193
11.7.1 Bv8 193
11.8 VEGF-B,-C,-D, and P1GF l93
11.9 Targeting MDSCs and TAMs '™
11.10 Targeting EPCs 195
11.11 Conclusions
References
12 Antibody-Based Vascular Tumor Targeting
Christoph Schliemann and Dario Neri
12.1 Concept and Definitions
12.2 Discovery of Novel Vascular Targets -
12.3 Validated Markers of the Tumor Vasculature. • •
12.3.1 Extra Domains of Fibronectin ¦
12.3.2 Large Isoforms of Tenascin C ¦ • 205
12.3.3 Phosphatidylserine -
x Contents
12.3.4 Annexin Al 206
12.3.5 Prostate-Specific Membrane Antigen (PSMA) 207
12.3.6 Endoglin 207
12.3.7 Integrins 207
12.3.8 Vascular Endothelial Growth Factors (VEGFs) and Receptors . 208
12.3.9 Nucleolin 208
12.4 Vascular Tumor Targeting: Imaging Applications 208
12.5 Vascular Tumor Targeting: Therapeutic Applications 209
References 212
13 Caveolae and Cancer 217
Kerri A. Massey and Jan E. Schnitzer
13.1 Vascular Endothelium 217
13.2 Caveolae Structure 218
13.3 Isolation of Caveolae 218
13.4 Caveolae in Signal Transduction 219
13.5 Caveolae as Active Transport Vesicles 220
13.6 Vascular Targeting 221
13.7 Phage Display Libraries 222
13.8 Large-Scale Approaches 223
13.9 Reducing Complexity 223
13.10 Tissue-Specific Targets 224
13.11 Tumor-Specific Targets 225
13.12 Clinical Implications 226
References 227 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV023078912 |
| callnumber-first | R - Medicine |
| callnumber-label | RC261 |
| callnumber-raw | RC261 |
| callnumber-search | RC261 |
| callnumber-sort | RC 3261 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 1800 |
| ctrlnum | (OCoLC)498875297 (DE-599)BVBBV023078912 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01878nam a2200481 cb4500</leader><controlfield tag="001">BV023078912</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20091217 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080114s2010 gw ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783540782803</subfield><subfield code="9">978-3-540-78280-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783540782810</subfield><subfield code="9">978-3-540-78281-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)498875297</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023078912</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC261</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 1800</subfield><subfield code="0">(DE-625)152873:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Angiogenesis inhibition</subfield><subfield code="c">Rüdiger Liersch ... (eds.)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 231 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Recent results in cancer research</subfield><subfield code="v">180</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiogenesis Inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neovascularization inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neovascularization, Pathologic</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Angiogenese</subfield><subfield code="0">(DE-588)4142449-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Inhibition</subfield><subfield code="0">(DE-588)4273127-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tumorwachstum</subfield><subfield code="0">(DE-588)4186432-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Tumorwachstum</subfield><subfield code="0">(DE-588)4186432-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Angiogenese</subfield><subfield code="0">(DE-588)4142449-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Inhibition</subfield><subfield code="0">(DE-588)4273127-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liersch, Rüdiger</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Recent results in cancer research</subfield><subfield code="v">180</subfield><subfield code="w">(DE-604)BV000000043</subfield><subfield code="9">180</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016281962&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016281962</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV023078912 |
| illustrated | Illustrated |
| index_date | 2024-07-02T19:36:16Z |
| indexdate | 2024-07-09T21:10:30Z |
| institution | BVB |
| isbn | 9783540782803 9783540782810 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016281962 |
| oclc_num | 498875297 |
| open_access_boolean | |
| owner | DE-29 DE-19 DE-BY-UBM DE-12 |
| owner_facet | DE-29 DE-19 DE-BY-UBM DE-12 |
| physical | XIV, 231 S. Ill., graph. Darst. |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Springer |
| record_format | marc |
| series | Recent results in cancer research |
| series2 | Recent results in cancer research |
| spelling | Angiogenesis inhibition Rüdiger Liersch ... (eds.) Berlin [u.a.] Springer 2010 XIV, 231 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Recent results in cancer research 180 Angiogenesis Inhibitors Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Angiogenese (DE-588)4142449-9 gnd rswk-swf Inhibition (DE-588)4273127-6 gnd rswk-swf Tumorwachstum (DE-588)4186432-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Tumorwachstum (DE-588)4186432-3 s Angiogenese (DE-588)4142449-9 s Inhibition (DE-588)4273127-6 s DE-604 Liersch, Rüdiger Sonstige oth Recent results in cancer research 180 (DE-604)BV000000043 180 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016281962&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Angiogenesis inhibition Recent results in cancer research Angiogenesis Inhibitors Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Angiogenese (DE-588)4142449-9 gnd Inhibition (DE-588)4273127-6 gnd Tumorwachstum (DE-588)4186432-3 gnd |
| subject_GND | (DE-588)4142449-9 (DE-588)4273127-6 (DE-588)4186432-3 (DE-588)4143413-4 |
| title | Angiogenesis inhibition |
| title_auth | Angiogenesis inhibition |
| title_exact_search | Angiogenesis inhibition |
| title_exact_search_txtP | Angiogenesis inhibition |
| title_full | Angiogenesis inhibition Rüdiger Liersch ... (eds.) |
| title_fullStr | Angiogenesis inhibition Rüdiger Liersch ... (eds.) |
| title_full_unstemmed | Angiogenesis inhibition Rüdiger Liersch ... (eds.) |
| title_short | Angiogenesis inhibition |
| title_sort | angiogenesis inhibition |
| topic | Angiogenesis Inhibitors Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Angiogenese (DE-588)4142449-9 gnd Inhibition (DE-588)4273127-6 gnd Tumorwachstum (DE-588)4186432-3 gnd |
| topic_facet | Angiogenesis Inhibitors Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Angiogenese Inhibition Tumorwachstum Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016281962&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000000043 |
| work_keys_str_mv | AT lierschrudiger angiogenesisinhibition |